TY - JOUR
T1 - From Glycocodeto Precision Oncology
T2 - Therapeutic Strategies Targeting Aberrant O -GalNAc Glycosylation in Cancer
AU - Aasted, Mikkel Koed Moller
AU - Jaroentomeechai, Thapakorn
AU - Dabelsteen, Sally
AU - Joshi, Hiren
AU - Stowell, Sean R.
AU - Wandall, Hans H.
PY - 2026
Y1 - 2026
N2 - Aberrant O-glycosylation is a prominent feature of cancer and contributes directly to multiple hallmarks of malignant transformation. Cancer-associated O-glycans include both truncated structures that are unique to mucin-type O-glycosylation and more elongated terminal motifs that function as ligands for glycan-binding proteins. Instead of representing a simple binary change from elongated to truncated structures, it is increasingly understood that these glycans decorate the cancer cell surface with a heterogeneous pattern of truncated, elongated, capped, and partially processed glycoforms, which coexist even on individual proteins and within the tumor glycocalyx. Functionally, truncated aberrant O-GalNAc glycans, such as Tn, STn, and T perturb epithelial differentiation, barrier integrity, signaling, and immunosuppression through interactions with glycan binding receptors, such as Siglecs and MGL. In addition, more elongated O-glycans, including Lewis antigens, interact with selectins promoting metastasis and cellular trafficking. Moreover, individual GalNAc-transferase isoenzymes, governing site-specific O-glycosylation, are emerging as context-dependent regulators of oncogenic processes through glycosylation of selected proteins. These observations establish cancer-associated O-glycans as context-dependent molecular drivers of tumor progression and promising therapeutic entry points. In this review, we discuss the expression, regulation, and functions of cancer-associated O-glycans, their roles in glycan-binding protein biology, and emerging therapeutic strategies that may enable a new generation of glycan-directed precision treatments in oncology.
AB - Aberrant O-glycosylation is a prominent feature of cancer and contributes directly to multiple hallmarks of malignant transformation. Cancer-associated O-glycans include both truncated structures that are unique to mucin-type O-glycosylation and more elongated terminal motifs that function as ligands for glycan-binding proteins. Instead of representing a simple binary change from elongated to truncated structures, it is increasingly understood that these glycans decorate the cancer cell surface with a heterogeneous pattern of truncated, elongated, capped, and partially processed glycoforms, which coexist even on individual proteins and within the tumor glycocalyx. Functionally, truncated aberrant O-GalNAc glycans, such as Tn, STn, and T perturb epithelial differentiation, barrier integrity, signaling, and immunosuppression through interactions with glycan binding receptors, such as Siglecs and MGL. In addition, more elongated O-glycans, including Lewis antigens, interact with selectins promoting metastasis and cellular trafficking. Moreover, individual GalNAc-transferase isoenzymes, governing site-specific O-glycosylation, are emerging as context-dependent regulators of oncogenic processes through glycosylation of selected proteins. These observations establish cancer-associated O-glycans as context-dependent molecular drivers of tumor progression and promising therapeutic entry points. In this review, we discuss the expression, regulation, and functions of cancer-associated O-glycans, their roles in glycan-binding protein biology, and emerging therapeutic strategies that may enable a new generation of glycan-directed precision treatments in oncology.
KW - C-type lectin
KW - Polypeptide n-acetylgalactosaminyltransferase
KW - Sialyl-lewis-x
KW - Acetyl-d-galactosamine
KW - Alpha-d-galactosamine
KW - Sialosyl-tn antigen
KW - Phase-i trial
KW - Active specific immunotherapy
KW - Humanized anti-cd22 antibody
KW - Metabolic labeling approach
U2 - 10.1021/acs.chemrev.5c00901
DO - 10.1021/acs.chemrev.5c00901
M3 - Review article
SN - 0009-2665
VL - 126
SP - 8957
EP - 9005
JO - Chemical Reviews
JF - Chemical Reviews
IS - 16
ER -